ATE305793T1 - Bakteriophage mit breitem wirtspektrum - Google Patents

Bakteriophage mit breitem wirtspektrum

Info

Publication number
ATE305793T1
ATE305793T1 AT01955955T AT01955955T ATE305793T1 AT E305793 T1 ATE305793 T1 AT E305793T1 AT 01955955 T AT01955955 T AT 01955955T AT 01955955 T AT01955955 T AT 01955955T AT E305793 T1 ATE305793 T1 AT E305793T1
Authority
AT
Austria
Prior art keywords
bacteriophage
broad host
host spectrum
spectrum
broad
Prior art date
Application number
AT01955955T
Other languages
English (en)
Inventor
Carl R Merril
Sankar Adhya
Deal Scholl
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE305793T1 publication Critical patent/ATE305793T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14211—Microviridae
    • C12N2795/14232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Toys (AREA)
  • Feedback Control In General (AREA)
AT01955955T 2000-07-25 2001-07-25 Bakteriophage mit breitem wirtspektrum ATE305793T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22098700P 2000-07-25 2000-07-25
PCT/US2001/023390 WO2002007742A2 (en) 2000-07-25 2001-07-25 Bacteriophage having multiple host range

Publications (1)

Publication Number Publication Date
ATE305793T1 true ATE305793T1 (de) 2005-10-15

Family

ID=22825862

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01955955T ATE305793T1 (de) 2000-07-25 2001-07-25 Bakteriophage mit breitem wirtspektrum

Country Status (8)

Country Link
US (1) US7163818B2 (de)
EP (1) EP1305038B1 (de)
AT (1) ATE305793T1 (de)
AU (1) AU2001278003A1 (de)
CA (1) CA2417188A1 (de)
DE (1) DE60113851T2 (de)
ES (1) ES2252263T3 (de)
WO (1) WO2002007742A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000508322A (ja) * 1996-04-15 2000-07-04 エヌワイエムオーエックス コーポレーション バクテリオファージを含有する組成物および感染症を治療するためのバクテリオファージの使用方法
EP1267192B1 (de) 2001-06-15 2009-02-18 Prysmian Cables & Systems Limited Verbinden optischer Fasern
ES2283581T3 (es) * 2001-07-18 2007-11-01 Instytut Immunologii I Terapii Doswiadczalnej-Pan Procedimientos de preparacion de bacteriofagos polivalentes para el tratamiento de infeccines bascterianas.
GB0209680D0 (en) * 2002-04-27 2002-06-05 Univ Strathclyde Immobilisation and stabilisation of bacteriophage
AU2003286402A1 (en) 2002-12-09 2004-06-30 Phage Biopharm Llc Production of bacteriophage compositions for use in phage therapy
GB0300597D0 (en) 2003-01-10 2003-02-12 Microbiological Res Authority Phage biofilms
US7951579B2 (en) * 2003-04-07 2011-05-31 Board of Trutees of the University of Arkansas Method for bacteriophage delivery and amplification
EP1663265B1 (de) 2003-07-23 2015-09-23 Biocontrol Limited Bakteriophagen-enthaltende medikamente
GB0320838D0 (en) 2003-09-05 2003-10-08 Univ Nottingham Disinfection of foodstuffs
US20090191254A1 (en) * 2004-12-06 2009-07-30 The Govt. Of The U.S.A., Centers For Disease Control And Prevention Inhibition of biofilm formation using bacteriophage
WO2006066224A2 (en) * 2004-12-14 2006-06-22 Yale University Virulence targeted antibiotics
CA2495138C (en) * 2005-01-20 2012-10-23 Alison Jane Basile Multiplexed analysis for determining a serodiagnosis of viral infection
WO2006095345A2 (en) * 2005-03-08 2006-09-14 Ramot At Tel-Aviv University Ltd. Targeted drug-carrying bacteriophages
AU2006268420B2 (en) 2005-07-12 2012-06-28 Micreos B.V. Bacteriophage and their uses
WO2007044428A2 (en) * 2005-10-05 2007-04-19 Internalle, Inc. Method for liberating bacteriophages and uses thereof
EP2004800B1 (de) 2006-04-04 2014-01-15 Henry Morris Krisch Verfahren zur herstellung von bakteriophagenzusammensetzungen sowie verfahren auf dem gebiet der phagentherapie
KR100781669B1 (ko) * 2006-06-20 2007-12-03 주식회사 인트론바이오테크놀로지 황색포도상구균 특이적 사멸능을 갖는 박테리오파지
KR100759988B1 (ko) * 2006-08-04 2007-09-19 주식회사 인트론바이오테크놀로지 황색포도상구균에 특이적인 항균 단백질
FR2910493B1 (fr) * 2006-12-20 2012-12-14 Bio Modeling Systems Ou Bmsystems Procede de diversification aleatoire d'une sequence genetique permettant de preserver l'identite de certains segments internes de ladite sequence genetique
FR2910492B1 (fr) * 2006-12-20 2013-02-15 Bio Modeling Systems Ou Bmsystems Procede de preparation de bacteriophages modifies par insertion de sequences aleatoires dans les proteines de ciblage desdits bacteriophages
GB0704553D0 (en) 2007-03-09 2007-04-18 Harper David R Beneficial effects of bacteriophage treatments
US20110143997A1 (en) * 2007-03-30 2011-06-16 Dow Agrosciences Llc Phage receptor binding proteins for antibacterial therapy and other novel uses
KR100910961B1 (ko) * 2007-09-13 2009-08-05 주식회사 인트론바이오테크놀로지 황색포도상구균의 균막 처치에 효과적인 박테리오파지 또는그것 유래의 용균단백질
US20100092431A1 (en) * 2008-05-15 2010-04-15 Auburn University Edwardsiella Ictaluri Bacteriophage and Uses Thereof
US8377866B2 (en) * 2009-02-12 2013-02-19 Intron Biotechnology, Inc. Antimicrobial protein derived from Podoviridae bacteriophage specific to Staphylococcus aureus
US9617314B2 (en) 2011-04-20 2017-04-11 National Taiwan University Polypeptides and bacteriophages specific to Klebsiella pneumoniae capsular type strains
WO2013010660A1 (en) * 2011-07-15 2013-01-24 Medizinische Hochschule Hannover (Mhh) Enzymes having alpha2,9 endosialidase activity
RU2518303C2 (ru) * 2012-06-29 2014-06-10 Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии имени Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН МНИИЭМ им. Г.Н. Габричевского Роспотребнадзора) КОМПОЗИЦИЯ АНТИБАКТЕРИАЛЬНАЯ, ШТАММ БАКТЕРИОФАГА Escherichia coli, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ ТАКОЙ КОМПОЗИЦИИ.
WO2015035168A1 (en) * 2013-09-05 2015-03-12 Massachusetts Institute Of Technolgy Tuning bacteriophage host range
EP2893933A1 (de) 2014-01-10 2015-07-15 Pherecydes Pharma Phagentherapie von E.coli-Infektionen
GB201417805D0 (en) * 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modifield bacteriophage
GB201417808D0 (en) * 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modified bacteriophage
GB201417810D0 (en) 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modifying bacteriophage
GB201417811D0 (en) * 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modifying bacteriophage
EP3018201A1 (de) 2014-11-07 2016-05-11 Pherecydes Pharma Phagentherapie
US10221398B2 (en) 2014-12-16 2019-03-05 C3J Therapeutics, Inc. Compositions of and methods for in vitro viral genome engineering
CA3020375A1 (en) 2016-04-08 2017-10-12 Phico Therapeutics Ltd Modified bacteriophage
CA3020371A1 (en) 2016-04-08 2017-10-12 Phico Therapeutics Ltd. Modifying bacteriophage
EP3532850A1 (de) * 2016-10-28 2019-09-04 Massachusetts Institute Of Technology Synthetische bakteriophagen und bakteriophagenzusammensetzungen
KR101822812B1 (ko) * 2017-02-22 2018-01-29 주식회사 인트론바이오테크놀로지 신규한 엔테로코쿠스 패슘 박테리오파지 Ent-FAP-4 및 이의 엔테로코쿠스 패슘 증식 억제 용도
US10174295B1 (en) 2017-08-01 2019-01-08 The Charles Stark Draper Laboratory, Inc. Composition of matter: engineering of Escherichia coli phage K1E
GB201712733D0 (en) 2017-08-08 2017-09-20 Snipr Tech Ltd Methods & cells
US20220348886A1 (en) * 2018-01-19 2022-11-03 Cytophage Technologies Inc. Genetically Engineered Bacteriophage
GB201901099D0 (en) 2019-01-27 2019-03-13 Snipr Biome Aps Methods, uses and compositions
AU2020312725B2 (en) * 2019-07-18 2025-12-18 Technische Universität München Host-independent expression of bacteriophages
CN112695017B (zh) * 2019-10-23 2022-04-15 吉林大学 噬菌体vB_Yen_X1及在防治鼠疫杆菌感染中应用
US11584781B2 (en) 2019-12-30 2023-02-21 Eligo Bioscience Chimeric receptor binding proteins resistant to proteolytic degradation
CN111876400B (zh) * 2020-08-06 2022-05-24 昆明理工大学 一种常温裂解酶Sly和编码此酶的多核苷酸
CN112143747B (zh) * 2020-09-09 2022-09-13 昆明理工大学 一种噬菌体裂解酶及其基因、基因重组表达载体与应用
CN113215114A (zh) * 2021-06-09 2021-08-06 西南石油大学 一种ndm-1大肠杆菌噬菌体及其分离方法和应用
CN120035659A (zh) 2022-06-29 2025-05-23 斯尼普生物群系有限公司 靶向大肠杆菌细胞
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
EP4621049A1 (de) * 2024-03-19 2025-09-24 Invitris GmbH Multispezifische partikel

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405720A (en) * 1981-03-04 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services Silver stains for protein in gels
US4508820A (en) * 1982-08-13 1985-04-02 The United States Of America As Represented By The Department Of Health And Human Services Method for simultaneously monitoring turnover rate in multiple proteins
US4555490A (en) * 1984-06-08 1985-11-26 The United States Of America As Represented By The Department Of Health And Human Services Rapid visualization system for gel electrophoresis
US4703016A (en) * 1986-05-05 1987-10-27 The United States Of America As Represented By The Department Of Health And Human Services Silver stain for rapid, quantitative detection of polypeptides and nucleic acids
US4940659A (en) * 1987-02-20 1990-07-10 Monoclonetics International, Inc. Screening extra-cellular body fluids for superoxide dismutase (SOD-1) for determining fetal trisomy 21 down syndrome
US4892814A (en) * 1987-06-22 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Method for distinguishing Creutzfeldt-Jakob disease from other dementias
US5817797A (en) * 1988-06-01 1998-10-06 The United States Of America As Represented By The Department Of Health And Human Services Sequencing DNA; a modification of the polymerase chain reaction
US5292665A (en) * 1989-03-15 1994-03-08 The United States Of America As Represented By The Department Of Health And Human Services Catalyst for preparing polyacrylamide gel which improves the detection of biomaterials by silver staining
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
WO1992010760A1 (en) * 1990-11-30 1992-06-25 Monoclonetics International, Incorporated Methods for the diagnosis of chronic lower back and cervical pain
US5468610A (en) * 1991-05-29 1995-11-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Three highly informative microsatellite repeat polymorphic DNA markers
US5861504A (en) * 1991-05-29 1999-01-19 The United States Of America As Represented By The Department Of Health And Human Services Eleven highly informative microsatelite repeat polymorphic DNA markers
US5378602A (en) * 1991-05-29 1995-01-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Highly informative microsatellite repeat polymorphic DNA markers twenty-[seven]six
US5429947A (en) * 1992-06-17 1995-07-04 Merril; Carl R. Diagnosing Alzheimer's disease and schizophrenia
US5811093A (en) * 1994-04-05 1998-09-22 Exponential Biotherapies, Inc. Bacteriophage genotypically modified to delay inactivations by the host defense system
CA2186962A1 (en) * 1994-04-05 1995-10-12 Richard M. Carlton Antibacterial therapy with genotypically modified bacteriophage
US20010043924A1 (en) * 1994-04-05 2001-11-22 Exponential Biotherapies, Inc. Antibacterial therapy with bacteriophage physico-chemically altered to delay inactivation by the host defense system
US5736388A (en) * 1994-12-30 1998-04-07 Chada; Sunil Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
SE506771C2 (sv) * 1996-02-06 1998-02-09 Gotpat 105 Ab Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
WO1998005344A1 (en) * 1996-08-05 1998-02-12 Brigham And Women's Hospital, Inc. Bacteriophage-mediated gene therapy
US20020177614A1 (en) * 2001-03-23 2002-11-28 Merril Carl R. Methods for treating nuerodegenerative diseases including alzheimer's
US7521479B2 (en) * 2001-04-16 2009-04-21 Panacea Pharmaceuticals, Inc. Methods of treating prion disease in mammals
EP1543169A4 (de) * 2002-01-23 2007-09-12 Us Gov Health & Human Serv Verfahren zur bestimmung der empfindlichkeit gegenüber bakteriophagen
US7399753B2 (en) * 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy

Also Published As

Publication number Publication date
DE60113851T2 (de) 2006-07-20
AU2001278003A1 (en) 2002-02-05
WO2002007742A9 (en) 2002-04-18
CA2417188A1 (en) 2002-01-31
WO2002007742A2 (en) 2002-01-31
WO2002007742A3 (en) 2002-08-08
EP1305038B1 (de) 2005-10-05
US20030216338A1 (en) 2003-11-20
EP1305038A2 (de) 2003-05-02
WO2002007742A8 (en) 2003-10-30
US7163818B2 (en) 2007-01-16
DE60113851D1 (de) 2006-02-16
ES2252263T3 (es) 2006-05-16

Similar Documents

Publication Publication Date Title
ATE305793T1 (de) Bakteriophage mit breitem wirtspektrum
ATE479683T1 (de) Antibakterielle mittel
TW200507841A (en) Antibacterial agents
CY1105349T1 (el) Θειαζολυλ-αναστολεις τυροκινασεων της οικογενειας tec
MY138285A (en) Fab i inhibitors
EA200600280A1 (ru) Композиции на основе производных липопептидных антибиотиков и способы их применения
ATE340171T1 (de) Piperazinderivate zur behandlung bakterieller infektionen
DE60307860D1 (de) Aminocyclohexenchinoline und ihre azaisosterischen analoga mit antibakterieller wirkung
EP1560821B8 (de) Antibakterielle wirkstoffe
DE69902526D1 (de) Verbesserung der antibakteriellen wirkung von oxazolidinon durch arginin derivate
WO2003099217A3 (en) Methods of treating bacterial infections and diseases associated therewith
ATE354585T1 (de) Antibakterielle amid-makrozyklen
ATE335499T1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
EP1567520A4 (de) Chinoline und stickstoffhaltige derivatedavon und deren verwendung als antibakterielle mittel
ATE510845T1 (de) Antibakterielle makrozyklen mit substituiertem biphenyl
UY28542A1 (es) Amidas macrocíclicas antibacterianas
BR0307085A (pt) Terapia combinada para o tratamento de infecções bacterianas
WO2004034961A3 (en) Antimicrobial agents and uses thereof
NO20010140D0 (no) Kjemotakse-inhiberende protein av Staphylo-Coccus (CHIPS) og dets anvendelse
ATE420852T1 (de) Verfahren und zusammensetzungen zur behandlung oder prävention von bakteriellen infektionen
BRPI0410967A (pt) compostos, composições e seus usos para o tratamento de infecções por vìrus da famìlia flaviviridae
AU2001265876A1 (en) Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases
AU2003259159A1 (en) N-aryl-2-oxazolidinones and their derivatives
SE0001631D0 (sv) New use
DE60326710D1 (de) Trizyklische antibakterielle makrolidderivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties